Moors & Cabot Inc. purchased a new position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 7,151 shares of the company’s stock, valued at approximately $1,155,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Aries Wealth Management increased its position in AstraZeneca by 1.3% during the third quarter. Aries Wealth Management now owns 4,546 shares of the company’s stock worth $741,000 after buying an additional 60 shares during the last quarter. Triumph Capital Management lifted its position in shares of AstraZeneca by 32.6% in the third quarter. Triumph Capital Management now owns 252 shares of the company’s stock valued at $41,000 after buying an additional 62 shares during the last quarter. Claro Advisors Inc. lifted its position in shares of AstraZeneca by 5.2% in the third quarter. Claro Advisors Inc. now owns 1,247 shares of the company’s stock valued at $201,000 after buying an additional 62 shares during the last quarter. Davis Investment Partners LLC boosted its stake in shares of AstraZeneca by 3.4% during the 3rd quarter. Davis Investment Partners LLC now owns 1,868 shares of the company’s stock worth $302,000 after acquiring an additional 62 shares during the period. Finally, Riversedge Advisors LLC boosted its stake in shares of AstraZeneca by 2.9% during the 3rd quarter. Riversedge Advisors LLC now owns 2,347 shares of the company’s stock worth $379,000 after acquiring an additional 67 shares during the period. Institutional investors own 20.35% of the company’s stock.
AstraZeneca Stock Up 0.1%
Shares of AZN opened at $184.66 on Monday. AstraZeneca Plc has a 52 week low of $153.41 and a 52 week high of $212.71. The firm has a market cap of $286.40 billion, a P/E ratio of 26.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24. The firm’s 50-day simple moving average is $168.82 and its 200 day simple moving average is $180.20. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.79 and a current ratio of 1.01.
AstraZeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.60 by $0.19. The firm had revenue of $16.21 billion for the quarter, compared to analysts’ expectations of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The business’s revenue was up 6.5% on a year-over-year basis. During the same period in the prior year, the firm earned $2.38 EPS. On average, analysts forecast that AstraZeneca Plc will post 10.22 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on AZN. Nordea Equity Research raised AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Weiss Ratings raised AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 26th. Zacks Research raised AstraZeneca from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Finally, CICC Research initiated coverage on shares of AstraZeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price objective for the company. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $206.67.
Get Our Latest Report on AstraZeneca
About AstraZeneca
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Further Reading
- Five stocks we like better than AstraZeneca
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
